LOXL2 and pancreatic neoplasm: Future experiments using genetically engineered mice with LOXL2-specific knockout in PSCs, or spontaneous pancreatic cancer mouse models, may provide more direct evidence of how increasing linear ECM alignment contributes to tumor progression.